An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer

Hong, Jeong Hee

doi:10.22465/kjuo.2022.20.4.207

Cited by 4 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the excellent performance of PSMA-PET, its use was limited in the Republic of Korea because of limitations in government insurance coverage and this may impact the results of this study. However, the coverage was recently extended to include PSMA-PET, and the requirement for PSMA-PET is expected to increase in the Republic of Korea [ 15 ]. Therefore, re-evaluation of the consensus regarding PSMA-PET is necessary for the future.…”

Section: Discussionmentioning

confidence: 99%

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

Yoo,

Park,

Rim

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Background: Interest in the oligometastatic prostate cancer (OMPC) is increasing, and various clinical studies have reported the benefits of metastasis-directed radiation therapy (MDRT) in OMPC. However, the recognition regarding the adopted definitions, methodologies of assessment, and therapeutic approaches is diverse among radiation oncologists. This study aims to evaluate the level of agreement for issues in OMPC among radiation oncologists. Methods: We generated 15 key questions (KQs) for OMPC relevant to definition, diagnosis, local therapies, and endpoints. Additionally, three clinical scenarios representing synchronous metastatic prostate cancer (mPC) (case 1), metachronous mPC with visceral metastasis (case 2), and metachronous mPC with castration-resistance and history of polymetastasis (case 3) were developed. The 15 KQs were adapted according to each scenario and transformed into 23 questions with 6–9 per scenario. The survey was distributed to 80 radiation oncologists throughout the Republic of Korea. Answer options with 0.0–29.9%, 30–49.9%, 50–69.9%, 70–79.9%, 80–89.9%, and 90–100% agreements were considered as no, minimal, weak, moderate, strong, and near perfect agreement, respectively. Results: Forty-five candidates voluntarily participated in this study. Among 23 questions, near perfect (n = 4), strong (n = 3), or moderate (n = 2) agreements were shown in nine. For the case recognized as OMPC with agreements of 93% (case 1), near perfect agreements on the application of definitive radiation therapy (RT) for whole metastatic lesions were achieved. While ≥70% agreements regarding optimal dose-fractionation for metastasis-directed RT (MDRT) has not been achieved, stereotactic body RT (SBRT) is favored by clinicians with higher clinical volume. Conclusion: For the case recognized as OMPC, near perfect agreement for the application of definitive RT for whole metastatic lesions was reached. SBRT was more favored as a MDRT by clinicians with a higher clinical volume.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

Yoo,

Park,

Rim

et al. 2024

Current Oncology

View full text Add to dashboard Cite

show abstract

“…PSMA I&T, which was developed as an improved derivative of PSMA-DOTAGA-FFK (Sub-KuE), was first reported by Weineisen and colleagues (Technische Universität Munchen) in 2015. Among these two PSMA ligands, PSMA-617 has been more frequently utilized in clinical practice because of it low rate of renal absorption [ 3 7 ].…”

Section: Usefulness Of Psma As a Therapeutic For Prostate Cancermentioning

confidence: 99%

“…Several domestic studies are in progress. As diagnostic PSMA ligands, 18 F-FC-303 (FutureChem Co. Ltd.) and 68 Ga-PSMA-NOTA-GUL (or 68 Ga-PSMA-NGUL) (CellBion Co. Ltd.) have been developed and are undergoing clinical testing; in addition, 177 Lu-FC705 (FutureChem Co. Ltd.) and 177 Lu-PSMA-DOTA-GUL (or 177 Lu-PSMA-DGUL) (CellBion Co. Ltd.) are under clinical testing for PSMA-targeted radioligand therapy [ 7 ].…”

Section: Current Status and Future Of Novel Psma Ligandsmentioning

confidence: 99%

The era of prostate-specific membrane antigen for the diagnosis and treatment of prostate cancer: A novel horizon

Song

Hong

2023

Investig Clin Urol

View full text Add to dashboard Cite

Development of an Automated Synthesizer for the Routine Production of Ga-68 Radiopharmaceuticals

PARK,

SON,

KANG

2023

Korean J Clin Lab Sci

View full text Add to dashboard Cite

The germanium-68/gallium-68 ( 68Ge/ 68 Ga) generator has high spatial utilization and requires little maintenance, making it economical and easy to produce. Thus, the frequency of use of 68 Ga radiopharmaceuticals is rapidly increasing worldwide. Therefore, this study attempted to develop an automated synthesizer for the routine clinical application of 68 Ga radiopharmaceuticals. The automated synthesizer was based on a fixed tubing system and the structure was designed after adjusting the position of the parts to reflect the synthesis method. Using various components that can be supplied in Korea, the automated synthesizer was manufactured at a much lower price cost than that of a commercialized automated synthesizer sold by companies. 68 Ga-DOTA-[Tyr3]-octreotide ( 68 Ga-DOTATOC) was synthesized to evaluate the performance of the automated synthesizer. 68Ga-DOTATOC could be synthesized with about 65% of non-decay corrected yield, and the synthesized 68 Ga-DOTATOC met all quality control standards. We have synthesized 68 Ga-DOTATOC more than 100 times, and only faced a few problems caused by mechanical errors. In this study, we successfully developed a simple automated synthesizer for 68 Ga radiopharmaceuticals with high reproducibility. As various 68 Ga radiopharmaceuticals have recently been developed, it is expected that the automated synthesizer developed in this study will be useful for routine clinical use.

show abstract

An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer

Cited by 4 publications

References 58 publications

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

The era of prostate-specific membrane antigen for the diagnosis and treatment of prostate cancer: A novel horizon

Development of an Automated Synthesizer for the Routine Production of Ga-68 Radiopharmaceuticals

Contact Info

Product

Resources

About